Novartis, Sun, Watson Strike Deal In Exelon MDL

Law360, New York (December 6, 2007, 12:00 AM EST) -- Sun Pharmaceutical Industries Ltd. and Watson Pharmaceuticals Inc. have ended their involvement in multidistrict litigation over Novartis AG's dementia and Alzheimer's drug Exelon with a settlement.

The parties filed a stipulation of dismissal with the U.S. District Court for the Southern District of New York on Monday. Novartis and defendants Watson Pharmaceuticals Inc., Watson Laboratories Inc. and Sun Pharmaceutical Industries Ltd. agreed to resolve the litigation without either side paying the other costs, disbursements or attorneys' fees, the stipulation said.

Novartis' claims against Dr. Reddy's Laboratories...
To view the full article, register now.

Law360 UK

UK Financial Services

Read Our Latest UK Legal News & Analysis

Financial Services Law360 UK and Insurance Law360 UK provide breaking news and in-depth analysis on U.K. and European Union regulation, enforcement, legislation, and litigation involving banks, investment firms, insurers, and more.